TC Biopharm (TCBP) Responds to Social Media Claims

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today refuted a false claim made earlier this week on social media, stating there is absolutely no way the company is in any danger of being delisted from the Nasdaq stock exchange.

The since deleted rumor stated that the company had filed an 8-K Notice to "Delist" from the Nasdaq and would transfer trading to a different exchange. TC BioPharm reiterated that there is no truth to this remark and that TC BioPharm remains in compliance with all Nasdaq listing requirements. The Company will look to take action to defend itself from these types of these attacks which are perpetrated in an effort to create negative market dynamics. If you have any additional questions, please reach out to the company directly at [email protected].

You May Also Be Interested In

• Cable One names Heather McCallion as chief operating officer
• Workday (WDAY) call put ratio 1 call to 1.1 puts on 34K contracts amid wide price movement
• Increasing unusual call option volume: CLBT STNE RIO INDA HTZ QSI HTZ SJM JACK EMN DLO